New Insights on SKYRIZI® and RINVOQ® Showcase Long-Term Efficacy in IBD Management at UEG Week 2026
In an exciting development in the treatment of inflammatory bowel disease (IBD), AbbVie showcased remarkable new data on October 17, 2026, at the United European Gastroenterology (UEG) Week in Barcelona, Spain. This presentation highlighted 20 scientific abstracts that reflect AbbVie’s ongoing commitment to excellence in IBD research. These findings revealed long-term clinical and endoscopic outcomes for its leading treatments, SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib), over a study period of nearly three years.
IBD, which includes chronic conditions like Crohn's disease and ulcerative colitis, necessitates innovative treatment approaches due to its complex and often debilitating nature. According to Pharm.D. Sofie Berg, who heads AbbVie’s immunology department, understanding patient responses over time is vital for effective long-term management. The data shared at this year’s UEGW conference adds a wealth of knowledge that can potentially guide clinicians toward achieving better long-term outcomes for patients living with IBD.
One of the most notable aspects of this presentation was the long-term efficacy data concerning moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). Not only did the results support previous findings, but they also underscored the sustained effectiveness of both SKYRIZI® and RINVOQ® in managing these chronic conditions.
An impressive real-world study, known as UPlift, also provided insight into how patients responded to upadacitinib. This interim analysis showed that 70.2% of patients with moderate to severe Crohn's disease experienced a clinical response within 12 weeks, with a median onset of response at just 13 days. Notably, patients who transitioned from TNF inhibitors to upadacitinib had lower hospitalization rates related to IBD and fewer surgeries over the following year.
AbbVie also introduced new data pertaining to a promising investigational dual-targeting therapy, ABBV-466. This therapy demonstrates potential in treating moderate-to-severe Crohn's disease by combining two mechanisms aimed at reducing inflammation. Presentations at UEGW offer a deeper understanding of ABBV-466 and its ability to lead to endoscopic remission, further contributing to AbbVie’s evolving portfolio in the IBD therapeutic landscape.
AbbVie’s ongoing commitment to addressing IBD is evident in its robust research programs. The company's dedication spans beyond merely exploring existing therapies; it actively pursues innovative treatments that could redefine standards of care in gastrointestinal health. With its focus on the long-term effects and real-world performance of its drugs, AbbVie is steadily building a comprehensive evidence base that not only validates its current therapies but also lays the groundwork for future advancements in IBD treatment.
As a consequence of these findings, healthcare providers may need to reconsider their treatment strategies, recognizing the importance of long-term treatment adherence and patient monitoring. With existing medications like RINVOQ® and SKYRIZI® demonstrating exceptional outcomes, we are entering a new era of tailored IBD management that promises improved quality of life for many patients.
AbbVie continues to inspire hope and possibility in the field of immunology, as they work diligently to uphold their mission of enhancing patient health and well-being worldwide.
IBD, which includes chronic conditions like Crohn's disease and ulcerative colitis, necessitates innovative treatment approaches due to its complex and often debilitating nature. According to Pharm.D. Sofie Berg, who heads AbbVie’s immunology department, understanding patient responses over time is vital for effective long-term management. The data shared at this year’s UEGW conference adds a wealth of knowledge that can potentially guide clinicians toward achieving better long-term outcomes for patients living with IBD.
Key Findings
One of the most notable aspects of this presentation was the long-term efficacy data concerning moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). Not only did the results support previous findings, but they also underscored the sustained effectiveness of both SKYRIZI® and RINVOQ® in managing these chronic conditions.
- - Risankizumab Results: In the COMMAND study for ulcerative colitis, substantial outcomes were achieved with risankizumab, showing clinical remission rates between 54.0% and 73.1% after 96 weeks of maintenance treatment. Meanwhile, endoscopic remission, which assesses internal inflammation levels, ranged from 38.8% to 53.5% in the same time frame.
- - Upadacitinib Results: For Crohn's disease, the U-ENDURE study reported that approximately 78.9% of patients on 15 mg and 86.6% on 30 mg achieved clinical remission after 144 weeks. Furthermore, endoscopic remission rates were documented at 47.1% and 64.2% for the respective dosages.
An impressive real-world study, known as UPlift, also provided insight into how patients responded to upadacitinib. This interim analysis showed that 70.2% of patients with moderate to severe Crohn's disease experienced a clinical response within 12 weeks, with a median onset of response at just 13 days. Notably, patients who transitioned from TNF inhibitors to upadacitinib had lower hospitalization rates related to IBD and fewer surgeries over the following year.
Advancements in Treatment Options
AbbVie also introduced new data pertaining to a promising investigational dual-targeting therapy, ABBV-466. This therapy demonstrates potential in treating moderate-to-severe Crohn's disease by combining two mechanisms aimed at reducing inflammation. Presentations at UEGW offer a deeper understanding of ABBV-466 and its ability to lead to endoscopic remission, further contributing to AbbVie’s evolving portfolio in the IBD therapeutic landscape.
Research and Development Commitment
AbbVie’s ongoing commitment to addressing IBD is evident in its robust research programs. The company's dedication spans beyond merely exploring existing therapies; it actively pursues innovative treatments that could redefine standards of care in gastrointestinal health. With its focus on the long-term effects and real-world performance of its drugs, AbbVie is steadily building a comprehensive evidence base that not only validates its current therapies but also lays the groundwork for future advancements in IBD treatment.
As a consequence of these findings, healthcare providers may need to reconsider their treatment strategies, recognizing the importance of long-term treatment adherence and patient monitoring. With existing medications like RINVOQ® and SKYRIZI® demonstrating exceptional outcomes, we are entering a new era of tailored IBD management that promises improved quality of life for many patients.
AbbVie continues to inspire hope and possibility in the field of immunology, as they work diligently to uphold their mission of enhancing patient health and well-being worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.